Ligand Pharmaceuticals, Inc. (LGNDZ) Stock Price & Analysis
Ligand Pharmaceuticals, Inc. (LGNDZ) — price $0.002276 (+33.88%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Ligand Pharmaceuticals, Inc. · LGNDZ
Ligand Pharmaceuticals, Inc. It operates on a licensing and royalty-based business model, featuring products like evomela and the OmniAb platform, while currently trading on the OTC market in the 'OTC Other' tier.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.002276 |
| Change on the day | +33.88% |
| 52-week range | $0.0017 – $0.002276 |
| Price / earnings (trailing) | 0.00 |
| Shares traded on the day | 4.5K |
Price & events
Other perspectives
Council score for Ligand Pharmaceuticals (LGNDZ): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the LGNDZ film — every key number, told as a short cinematic story
~2 min · open the film
What is Ligand Pharmaceuticals (LGNDZ), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ligand Pharmaceuticals, Inc. (LGNDZ) is the company analyzed here. It employs 47 people and is led by Todd C. Davis. In Q2 FY2026 it reported revenue of $64M and net income of $49M.
What do the latest results show for Ligand Pharmaceuticals (LGNDZ)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $64M. Against analyst estimates the company has EPS beat 7 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $64M | $49M | $2.22 (diluted) |
| Q1 FY2026 | $52M | -$13M | -$0.67 (diluted) |
| Q4 FY2025 | $60M | $45M | $2.12 (diluted) |
| Q3 FY2025 | $115M | $117M | $5.81 (diluted) |
What are the financial strengths and risks for Ligand Pharmaceuticals (LGNDZ)?
Short answer
The distress and quality screens read Altman Z 1.47 · Piotroski F 5. Trailing ratios: ROE 16.2% · ROA 10.0% · current ratio 21.28 · earnings yield 2.4% · free-cash-flow yield 1.9%.
What has been published about Ligand Pharmaceuticals (LGNDZ)?
What Investors Ask About Ligand Pharmaceuticals (LGNDZ)
These answers are editorial: 1 of these 1 answer is drawn from the LGNDZ research dossier (written Jun 14, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What are the implications of Ligand Pharmaceuticals, Inc.'s OTC Other tier listing?
Ligand Pharmaceuticals, Inc.'s listing on the 'OTC Other' tier of the OTC market carries several significant implications for investors. This tier is typically reserved for companies that do not meet the financial or disclosure standards of higher OTC tiers or major exchanges like NASDAQ or NYSE.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.002276 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T17:24:47.613Z. | |
px.change | Change on the day | +33.88% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | +$0.000576 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 4.5K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $64M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $49M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.0017 – $0.002276 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 47 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Todd C. Davis | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 1.47 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-09-18 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 16.2% · ROA 10.0% · current ratio 21.28 · earnings yield 2.4% · free-cash-flow yield 1.9% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.